Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01363817 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
A Phase 1 study of Lymphoblastic Leukemia, Acute T-cell and Precursor T-Cell Lymphoblastic Lymphoma, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
- 6
- Study locations
NCT01363817 is a Phase 1 study of Lymphoblastic Leukemia, Acute T-cell and Precursor T-Cell Lymphoblastic Lymphoma that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 31 participants. The trial reports 6 study locations across 4 states.
The verdict
NCT01363817, a Phase 1 study of Lymphoblastic Leukemia, Acute T-cell and Precursor T-Cell Lymphoblastic Lymphoma, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to identify a safe and tolerable dose of BMS-906024, either alone or in combination with Dexamethasone in subjects with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma who no longer respond to or have relapsed from standard therapies
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG BMS-906024
Study Locations (6)
Other
- Local Institution - Marseille
- Local Institution - Paris
- Johann Wolfgang Goethe Universitaet - Frankfurt am Main
Massachusetts
- Dana Farber Cancer Institute - Boston
New York
- Memorial Sloan Kettering Cancer Center - New York
Texas
- The University Of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2011-09-28 |
| Est. Completion | 2018-02-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01363817
The ClinicalTrials.gov registry entry for NCT01363817 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lymphoblastic Leukemia, Acute T-cell appearing as the primary indexed condition, and to 2 interventions - of which Dexamethasone is the first listed.
NCT01363817 reports 6 study locations spanning 4 distinct geographic areas - top geographies include Other, Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT01363817 about?
NCT01363817 is a clinical study titled "Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma". The purpose of this study is to identify a safe and tolerable dose of BMS-906024, either alone or in combination with Dexamethasone in subjects with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma who no longer respond to or have relapsed from standard therapies
What is the current status of trial NCT01363817?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2011-09-28. Estimated completion is 2018-02-07.
What conditions does trial NCT01363817 study?
This clinical trial studies the following conditions: Lymphoblastic Leukemia, Acute T-cell, Precursor T-Cell Lymphoblastic Lymphoma.
What interventions are being tested in trial NCT01363817?
The interventions under investigation include: Dexamethasone (DRUG), BMS-906024 (DRUG).
Who is sponsoring clinical trial NCT01363817?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01363817 being conducted?
This trial has 6 study locations across Massachusetts, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Lymphoblastic Leukemia, Acute T-cell
All registered trials for this condition
Precursor T-Cell Lymphoblastic Lymphoma
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.